Literature DB >> 11435427

Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor.

C C Taggart1, G J Lowe, C M Greene, A T Mulgrew, S J O'Neill, R L Levine, N G McElvaney.   

Abstract

A number of serine proteases, matrix metalloproteases, and cysteine proteases were evaluated for their ability to cleave and inactivate the antiprotease, secretory leucoprotease inhibitor (SLPI). None of the serine proteases or the matrix metalloproteases examined cleaved the SLPI protein. However, incubation with cathepsins B, L, and S resulted in the cleavage and inactivation of SLPI. All three cathepsins initially cleaved SLPI between residues Thr(67) and Tyr(68). The proteolytic cleavage of SLPI by all three cathepsins resulted in the loss of the active site of SLPI and the inactivation of SLPI anti-neutrophil elastase capacity. Cleavage and inactivation were catalytic with respect to the cathepsins, so that the majority of a 400-fold excess of SLPI was inactivated within 15 min by cathepsins L and S. Analysis of epithelial lining fluid samples from individuals with emphysema indicated the presence of cleaved SLPI in these samples whereas only intact SLPI was observed in control epithelial lining fluid samples. Active cathepsin L was shown to be present in emphysema epithelial lining fluid and inhibition of this protease prevented the cleavage of recombinant SLPI added to emphysema epithelial lining fluid. Taken together with previous data that demonstrates that cathepsin L inactivates alpha(1)-antitrypsin, these findings indicate the involvement of cathepsins in the diminution of the lung antiprotease screen possibly leading to lung destruction in emphysema.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435427     DOI: 10.1074/jbc.M103220200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Reovirus variants selected for resistance to ammonium chloride have mutations in viral outer-capsid protein sigma3.

Authors:  Kimberly M Clark; J Denise Wetzel; Yingqi Gu; Daniel H Ebert; Stephanie A McAbee; Emily K Stoneman; Geoffrey S Baer; Yuwei Zhu; Gregory J Wilson; B V V Prasad; Terence S Dermody
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal.

Authors:  Morris D Cooper; Melissa H Roberts; Ona L Barauskas; Gary A Jarvis
Journal:  Am J Reprod Immunol       Date:  2012-04-26       Impact factor: 3.886

4.  Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

5.  Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers.

Authors:  Megan Meyer; Rebecca N Bauer; Blanche D Letang; Luisa Brighton; Elizabeth Thompson; Rosalia C M Simmen; James Bonner; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-27       Impact factor: 5.464

6.  Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.

Authors:  Anushka C Galasiti Kankanamalage; Yunjeong Kim; Pathum M Weerawarna; Roxanne Adeline Z Uy; Vishnu C Damalanka; Sivakoteswara Rao Mandadapu; Kevin R Alliston; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas
Journal:  J Med Chem       Date:  2015-03-19       Impact factor: 7.446

7.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

8.  Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions.

Authors:  Mickey V Patel; Mimi Ghosh; John V Fahey; Christina Ochsenbauer; Richard M Rossoll; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2014-05-08       Impact factor: 3.886

9.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

10.  Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.

Authors:  Irina Petrache; Joud Hajjar; Michael Campos
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.